Takeda Pharmaceutical (NYSE: TAK) reveals fiscal year 2023 results & restructuring plan. Revenue up 5.9%, net profit down 54.6%. Expecting operating profit of 225 billion yen in 2024.
Jaguar's novel plant-based prescription drug crofelemer has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both MVID and SBSSAN FRANCISCO, CA / ACCESSWIRE / May 9, 2024 / Jaguar
-Preclinical findings show exosome-based therapeutic approach for the treatment of arginase-1 deficiency (ARG1-D)- -Presentation to be featured in an oral session being held on May 9, 2024-SAN DIEGO, May 09, 2024
Early non-human primate (NHP) data for P-KLKB1-101 demonstrate successful liver gene editing approaching human therapeutic range with a favorable safety and tolerability profilePreclinical P-FVIII-101 data highlight
In preclinical models of cornea endothelial dystrophies, a Surrozen antibody-based Wnt mimetic reduced corneal edema and stimulated endothelial cell proliferation in the cornea Surrozen's antibody based Wnt mimetic
Ascendis Pharma A/S (NASDAQ:ASND) today announced that new TransCon PTH (palopegteriparatide) data supporting clinical and quality-of-life benefits in adult patients with chronic hypoparathyroidism will be presented at
Akoya Biosciences, Inc. (NASDAQ:AKYA), The Spatial Biology Company®, and NeraCare, a leading developer of laboratory tests for the prognosis of melanoma patients, announced an exclusive agreement today under which
Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present clinical
-GAD Diagnosis Increases Healthcare Costs and Decreases Work Productivity and Health-Related Quality of Life--People with Undiagnosed GAD Incur Even Higher Total Healthcare Costs than those Diagnosed with